Margetuximab

马吉妥昔单抗

Report date: 2026/04/27 20:02:09

Base Information

Drug NameMargetuximab
Drug Alias Namemargetuximabum玛格妥昔单抗margetuximabmargetuximab-cmkbAnti-HER2-monoclonal-antibody (Macrogenics) +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsNeoplasm Metastasis +[9] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2020/12/16
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRaven Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesGC Biopharma CorpZai Lab (Shanghai) Co LtdTersera Therapeutics Llc +[5] 
Inactive CompaniesDana-Farber Cancer InstituteBaxter Pharmaceutical Solutions Llc
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsNeoplasm Metastasis +[5] 
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG